Arthneeti

Bafna Pharmaceuticals Share Price & Earnings Call Analysis

₹430.20-1.99% today
Market cap
₹1,018 Cr
P/E
130.64
ROE
12.27%
PEG
-1088.71
Price to sales
7.13
Debt to equity
0.39
52W high / low
₹471 / ₹99.2
Sales growth (5Y)
16.16%
EBITDA margin
8.26%
Net profit margin
7.37%
Promoter holding
75.00%
Sales (last year)
₹143 Cr

Incorporated in 1981, Bafna Pharmaceuticals Ltd manufactures finished pharmaceutical formulations[1]

Potential multibaggers · Q2 FY27

Potential multibaggers in Pharmaceuticals & Biotechnology
on management's own guidance

  1. Strong growth
    2
  2. Strong growth
    1
  3. Strong growth
    3
See all potential multibaggersWhere does Bafna Pharmaceuticals rank?

Portfolio builder

Build your portfolio
from the top-ranked stocks

  1. 1. Pick 3–15 stocks
  2. 2. Choose large, mid or small cap and your sectors
  3. 3. Get a portfolio built from the rankings
Build my portfolio

Ranks describe management commentary on revenue and margin from the latest earnings call. Not investment advice.

Peers

Pharmaceuticals & Biotechnology companies ranked on guidance

#CompanyRevenue guidedMargin guidedMarket capP/E
140%+Up 2%+₹480 Cr19.1
240%+Up 0–2%₹212 Cr16.1
340%+Flat₹17,925 Cr—
440%+Flat₹5,223 Cr39.1
540%+Flat₹4,268 Cr—
640%+Flat₹40 Cr—

Sign up free to see every company in the sector ranking and track Bafna Pharmaceuticals.

Pro shows every company guiding 40%+ revenue growth →Full Pharmaceuticals & Biotechnology ranking

Financials of Bafna Pharmaceuticals

Quarterly Results, Profit & Loss, Balance Sheet, Cash Flows, and Ratios are shown below as separate sections.

Financials of Bafna Pharmaceuticals

Quarterly Results

Quarter-by-quarter operating performance

Dec 2022Mar 2023Jun 2023Sep 2023Dec 2023Mar 2024Jun 2024Sep 2024Dec 2024Mar 2025Jun 2025Sep 2025Dec 2025
Sales +34.2242.2441.9540.6828.4441.4033.2940.3233.1939.0634.6235.4738.29
Expenses +31.1834.6235.6636.6730.5138.5132.0836.5330.1335.9529.5531.1935.24
Operating Profit3.047.626.294.01-2.072.891.213.793.063.115.074.283.05
OPM %8.88%18.04%14.99%9.86%-7.28%6.98%3.63%9.40%9.22%7.96%14.64%12.07%7.97%
Other Income +1.930.261.870.160.980.520.161.020.18-0.760.601.181.22
Interest0.580.700.600.440.580.680.650.620.640.820.910.860.86
Depreciation1.401.531.211.241.271.271.441.581.660.221.371.471.57
Profit before tax2.995.656.352.49-2.941.46-0.722.610.941.313.393.131.84
Tax %0.00%4.96%0.00%0.00%0.00%0.00%0.00%0.00%0.00%0.00%0.00%0.00%0.00%
Net Profit +3.005.376.352.48-2.941.46-0.722.620.951.313.393.121.84
EPS in Rs1.272.272.681.05-1.240.62-0.301.110.400.551.431.320.78

Financials of Bafna Pharmaceuticals

Profit & Loss

Annual income statement trend

Mar 2014Mar 2015Mar 2016Mar 2017Mar 2018Mar 2019Mar 2020Mar 2021Mar 2022Mar 2023Mar 2024Mar 2025TTM
Sales +17710085654644427185115152146147
Expenses +15611682708157416173100141135132
Operating Profit21-163-5-35-131101216111116
OPM %12%-16%3%-8%-77%-30%3%14%14%14%7%8%11%
Other Income +14011310-231-03412
Interest12121211720112233
Depreciation8544433455555
Profit before tax26-13-19-14-18-2565127410
Tax %40%-0%-3%-4%15%8%0%0%0%2%0%0%
Net Profit +16-12-18-16-20-2565117410
EPS in Rs0.723.28-6.53-9.90-6.95-8.34-106.532.462.214.793.111.754.08
Dividend Payout %0%0%0%0%0%0%0%0%0%0%0%0%

Financials of Bafna Pharmaceuticals

Balance Sheet

Capital structure and asset base

Mar 2014Mar 2015Mar 2016Mar 2017Mar 2018Mar 2019Mar 2020Mar 2021Mar 2022Mar 2023Mar 2024Mar 2025Sep 2025
Equity Capital1919191924242242424242424
Reserves5053412617-349333850576168
Borrowings +9964808247463151123242832
Other Liabilities +54504540405417141733424037
Total Liabilities223185185167128121718690130148153161
Fixed Assets +63494743403735363940405965
CWIP000000010212715
Investments1181818110000000
Other Assets +158118120106868236505188958781
Total Assets223185185167128121718690130148153161

Financials of Bafna Pharmaceuticals

Cash Flows

Operating, investing and financing cash movement

Mar 2014Mar 2015Mar 2016Mar 2017Mar 2018Mar 2019Mar 2020Mar 2021Mar 2022Mar 2023Mar 2024Mar 2025
Cash from Operating Activity +19-314-7-1-34-14105922
Cash from Investing Activity +-556-1-838433-5-7-7-15-21
Cash from Financing Activity +-14-664-5-31-2712-510-11
Net Cash Flow-18-00-0006-7-28-62
Free Cash Flow-12-52040-1-36-202-2-60
CFO/OP6%-74%-106%-263%20%8%-2,786%-132%83%32%87%194%

Financials of Bafna Pharmaceuticals

Ratios

Working capital efficiency and return ratios

Mar 2014Mar 2015Mar 2016Mar 2017Mar 2018Mar 2019Mar 2020Mar 2021Mar 2022Mar 2023Mar 2024Mar 2025
Debtor Days192303291302195208524963130109101
Inventory Days786692118102122208154185129125127
Days Payable116149169164265517229107113165149140
Cash Conversion Cycle15522021425531-1883196135948488
Working Capital Days4156125-36-108-210891211231049274
ROCE %9%-13%-0%-6%-35%-21%-3%10%11%16%9%8%
99out of 100

Momentum score · price trend

99 out of 100 — Strengthening

Over the past year its share price has done better than most of the stocks we track.

PeriodShare price changeBetter than … of 1,910 stocks
Last 12 months+205.6%98%
Last 6 months+225.3%100%
Last 3 months+63.7%99%
How we calculate it

“Better than 30%” means that over that period the share price did better than 30 out of every 100 stocks we track (1,910 Indian companies worth ₹500 Cr or more, with at least a year of prices).

The score weighs the longer periods more: 40% × 12-month + 40% × 6-month + 20% × 3-month. For Bafna Pharmaceuticals: 0.4 × 98 + 0.4 × 100 + 0.2 × 99 = 99.

Strengthening is 70 and above, Steady 40 to 70, Cooling below 40. Scores are recalculated every night after the market closes.

Full methodology →

This describes only how the share price has moved up to 2 Nov 2026, compared with other stocks. It says nothing about the business, and it is not a prediction, a price target or a recommendation to buy or sell.

Continue your research

Others in Pharmaceuticals & Biotechnology this season

  • Anthem Bioscienc (Q2 FY27)

    Q2FY27 Consolidated Revenue from Operations: ₹5,940 Mn, up 7.9% YoY from ₹5,505 Mn in Q2FY26 (Page 4). Key investor presentation takeaways from Anthem Bioscienc

  • Neuland Laboratories (Q2 FY27)

    Q2FY27 Total Income (revenue) was ₹457.2 crore, down 11.4% year-on-year (YoY) from Q2FY26. Key investor presentation takeaways from Neuland Laboratories Ltd's Q

  • Hikal (Q2 FY27)

    Consolidated Revenue Q2FY27:** ₹434 crores, up 36% YoY from ₹319 crores in Q2FY26 (Page 9) . Key investor presentation takeaways from Hikal Ltd's Q2 FY27 invest

  • Kopran (Q2 FY27)

    9,335 lakhs (~79% increase) . Key investor presentation takeaways from Kopran Ltd's Q2 FY27 investor presentation — and how it ranks against sector peers.

Compare:vs Sun Pharmaceutical Industriesvs Divis Laboratoriesvs Torrent Pharmaceuticals